Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer

被引：0

作者：

Masahiro Nozawa

Hirofumi Mukai

Shunji Takahashi

Hiroji Uemura

Takeo Kosaka

Yusuke Onozawa

Jun Miyazaki

Kazuhiro Suzuki

Koji Okihara

Yoichi Arai

Tomomi Kamba

Masashi Kato

Yasutomo Nakai

Hiroshi Furuse

Haruki Kume

Hisamitsu Ide

Hiroshi Kitamura

Akira Yokomizo

Takahiro Kimura

Yoshihiko Tomita

Keiji Ohno

Yoshiyuki Kakehi

机构：

[1] Kinki University,Department of Urology, Faculty of Medicine

[2] National Cancer Center Hospital East,Department of Medical Oncology

[3] The Cancer Institute Hospital of JFCR,Department of Urology

[4] Yokohama City University Graduate School of Medicine,Department of Urology

[5] Keio University School of Medicine,Division of Clinical Oncology

[6] Shizuoka Cancer Center,Department of Urology, Institute of Clinical Medicine

[7] University of Tsukuba,Department of Urology

[8] Gunma University Graduate School of Medicine,Department of Urology

[9] Kyoto Prefectural University of Medicine,Department of Urology

[10] Tohoku University Hospital,Department of Urology

[11] Kyoto University Graduate School of Medicine,Department of Urology

[12] Nagoya University Graduate School of Medicine,Department of Urology

[13] Osaka University Graduate School of Medicine,Department of Urology, Graduate School of Medical Sciences

[14] Hamamatsu University School of Medicine,Department of Urology

[15] The University of Tokyo Hospital,undefined

[16] Teikyo University Hospital,undefined

[17] Sapporo Medical University Hospital,undefined

[18] Kyushu University,undefined

[19] The Jikei University Hospital,undefined

[20] Yamagata University Hospital,undefined

[21] Sanofi K.K.,undefined

[22] Kagawa University Faculty of Medicine,undefined

[23] Osaka Medical Center for Cancer and Cardiovascular Diseases,undefined

[24] Niigata University,undefined

来源：

International Journal of Clinical Oncology | 2015年 / 20卷

关键词：

Adverse event; Cabazitaxel; Japan; Neutropenia; Phase I; Prostate cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1026 / 1034

页数：8

共 38 条

[1]

Pienta KJ(2006)Mechanisms underlying the development of androgen-independent prostate cancer Clin Cancer Res 12 1665-1671

[2]

Bradley D(2008)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 242-245

[3]

Berthold GR(2014)Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics Cancer Metastasis Rev 33 555-566

[4]

Pond F(2013)Preclinical antitumor activity of cabazitaxel, a semi-synthetic taxane active in taxane-resistant tumors Clin Cancer Res 19 2973-2983

[5]

Soban D(2013)Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study Eur J Cancer 49 25-34

[6]

Mukherji A(2009)Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1 h infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 723-730

[7]

Omlin C(2014)Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer Cancer Chemother Pharmacol 73 703-710

[8]

Pezaro P(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2 228-247

[9]

Vrignaud D(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154

[10]

Sémiond P(2012)Cabazitaxel (cbz) + prednisone (P; CbzP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): interim results from compassionate-use programme (CUP) and early-access programme (EAP) Ann Oncol 23 931-897

← 1 2 3 4 →